ancomycin is a glycopeptide antibiotic that is widely used for treatment of resistant gram-positive organisms [1] [2] [3] [4] . Augmented Renal Clearance (ARC) is a complex issue for antibiotics' dose adjustment [1] [2] [3] . This phenomenon is defined as a creatinine clearance (CrCl) more than 130 ml/min [2, 4] . This phenomenon is common in early phase of sepsis [2, 4] . According to the sepsis guideline, vancomycin is recommended to cover gram-positive organisms [5] . Serum vancomycin trough levels between 10-15 mg/l and 15-20 mg/l are recommended for mild to moderate and severe infections respectively [6] . There are some evidences that even in serum vancomycin trough levels less than 15 mcg/l patients had acceptable clinical response renal safety [7] [8] [9] . Serum vancomycin trough level is a surrogate marker of targeted AUC/MIC (area under the curve/minimum inhibitory concentration) index [6] . In recent study, both patients with serum vancomycin trough levels≥ 15 mg/l and <15 mg/l reached the targeted AUC/MIC [10] . In this study clinical response and microbiological clearance were compared in septic patients in ARC phase with serum vancomycin trough levels≥ 15 mg/l and< 15 mg/l.
Methods
In this observational study, the information of 39 septic patients in ARC phase from ICU wards of Imam Khomeini Hospital Complex were recorded. Vancomycin had been administered with a loading dose of 25 mg/kg initially and then with maintenance doses of 15 mg/kg every 8 hours. Vancomycin trough concentration had been measured before the fourth dose of vancomycin, and dose adjustment had been done if necessary. After that, another trough concentration was measured at day of four. The breakpoint for trough concentration was considered 15 mg/l. Patients were stratified by serum trough concentration of vancomycin in fourth day into two groups (less than 15mg/l versus equal or more than 15mg/l). Because the treatment response to vancomycin is delayed, the trough concentration in fourth day was considered for data analysis. Clinical response and microbiological clearance were considered as main outcomes of the study. Clinical response was defined as reversal of Systemic Inflammatory Response Syndrome (SIRS) parameters. If positive cultures became negative after 72 h of vancomycin therapy it was considered as microbiological clearance. Data were analysed with SPSS version 21. Distribution of data was assessed with Kolmogorov-Smirnov normality test. Categorical data was reported as a number and percentage. Continuous data was reported as mean ± SD. In statistical analysis, p value less than 0.05 was considered as statistical significant.
Results
During this study, 39 patients were included. Twenty-two and 17 patients had serum vancomycin trough levels <15 mg/l and ≥15 mg/l respectively. Most of the patients received meropenem as a concomitant antibiotic with vancomycin. The patients did not significantly differ in terms of demographic and baseline characteristics ( Table 1) . The vancomycin pharmacokinetic parameters are summarized in (Table 2) .
Clinical response and microbiological clearance were assessed at day 4 of treatment. From 22 patients with serum vancomycin trough concentration <15 mg/l, 19 patients had clinical response. From 17 patients with trough concentration ≥15 mg/l, 13 patients had clinical response. The clinical response was not different between the groups (p= 0.677). Only 16 patients in this study had positive blood cultures and microbiological clearance was similar between the groups (p= 1.00). Clinical response and microbiological clearance data are shown in (Table 3) . 
Discussion
In this study, the clinical response and microbiological clearance were not different between patients with serum vancomycin trough levels≥ 15 mg/l and patients with serum vancomycin trough levels< 15 mg/l.
In patients with pneumonia, endocarditis and osteomyelitis due to MRSA, clinical was not different between the two groups with trough concentration less than 15 mg/l and more than 15 mg/l. But the rate of vancomycin induced nephrotoxicity (VIN) was more in patients with higher vancomycin trough concentration (≥15 mg/l). However microbiological clearance was not assessed in this study [11] .
In another observational study, found a correlation was not found between serum vancomycin trough concentration and time to normalization of clinical signs and symptoms. However serum trough levels of vancomycin were negatively correlated with CrCl values [12] .
In a systematic review and meta-analysis, all-cause mortality was assumed as a main outcome. Mortality was not significantly different between patients with serum trough concentration of vancomycin less than 15 mg/l versus patients with serum vancomycin trough levels≥ 15 mg/l. In sub-group analysis, in patients with pneumonia, the mortality was significantly higher in patients with low trough levels compared to patients with high trough levels. However this comparison was not statistically significant in patients with bacteraemia. Microbiological failure (persistent bacteraemia≥ 7 days) was significantly higher in patients with vancomycin serum trough levels< 15 mg/l. Also, incidence of VIN was significantly higher in patients with serum vancomycin trough levels≥ 15 mg/l [7] [8] 10] .
High serum trough level of vancomycin (≥ 15 mg/l) is an independent risk factor for nephrotoxicity [9] [10] . Patients in ARC phase need higher doses of vancomycin to reach the therapeutic levels 3). TDM of vancomycin is recommended in these patients. In recent studies, AUC/MIC index was recommended for TDM of vancomycin [13] [14] . However there is still no precise correlation between serum trough concentration and AUC/MIC index of vancomycin.
Optimum serum vancomycin level is not defined to predict both efficacy and safety of vancomycin yet. However severity of infection and baseline renal function are two important determinants. Also, the MIC of vancomycin for culprit microorganism is very important to make a decision for treatment strategy.
This study suffered from some limitations. Small sample size, observational design and including patients with different types of infections are main concerns. However this study was the first one that evaluated clinical and microbiological responses in septic patients during ARC phase.
Conclusion
In this study, clinical response and microbiological clearance were comparable in patients with serum vancomycin levels< 15 mg/l and ≥15 mg/l. This finding should be examined in future clinical trials with adequate sample sizes.
